<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

CU Cancer Center News and Stories

Breast Cancer

Research    Breast Cancer

Seeking a Unique Treatment for Lobular Breast Cancer

Though the two main histological types of breast cancer — lobular and ductal — are treated with the same hormonal therapies, women with lobular breast cancer often have recurrence or metastasis of the disease several years after their initial treatment.

Author Greg Glasgow | Publish Date July 28, 2021
Full Story

Research    Breast Cancer

Promising New Research for Metastatic Breast Cancer

A discovery by CU Cancer Center member Traci Lyons, PhD, is providing new hope for women with metastatic breast cancer.

Author Greg Glasgow | Publish Date June 25, 2021
Full Story

Breast Cancer

COVID-19 Vaccines Can Cause Lumps That Mimic Breast Cancer

The COVID-19 vaccines are beginning to significantly slow the spread of the virus, but the Pfizer and Moderna and vaccines are having an unforeseen consequence for breast cancer doctors. The vaccines often cause swelling in the armpit or underarm that can mimic the lumps associated with breast cancer, causing some women undue concern.

Author Greg Glasgow | Publish Date June 03, 2021
Full Story

Patient Care    Community    Breast Cancer

Breast Cancer Patient’s Advice: Take It One Treatment at a Time

It feels odd to use the phrase “perfect timing” when talking about a cancer diagnosis, but that’s exactly how Tonya Quinn describes her experience being diagnosed with breast cancer two years ago.  

Author Valerie Gleaton | Publish Date May 12, 2021
Full Story

Research    Patient Care    Breast Cancer    Surgical Oncology

Improving Quality of Life for Breast Cancer Patients

Though breast cancer patients are now living longer than ever before, treatments for the disease can have wide-ranging effects on their long-term quality of life. Physical, social, and sexual wellbeing all can be impacted by radiation, chemotherapy, surgery, antiendocrine therapy and other challenges that go along with a breast cancer battle.

Author Greg Glasgow | Publish Date March 23, 2021
Full Story

Research    Breast Cancer

The Role of T Cells in Fighting Cancer

New research from CU Cancer Center member Jing Hong Wang, MD, PhD, and recent University of Colorado Immunology program graduate Rachel Woolaver, PhD, may help researchers develop more effective personalized immunotherapy for cancer patients.

Author Greg Glasgow | Publish Date January 14, 2021
Full Story

Patient Care    Breast Cancer

BFitBWell Strengthens Cancer Survivors

In late 2019, two remarkable women were brought together by a shared experience that could only happen at the University of Colorado Anschutz Health & Wellness Center. Through their participation in the BFitBWell Program for cancer survivors, they found renewed strength and friendship.

Author Cancer Center | Publish Date June 30, 2020
Full Story

Research    Breast Cancer

Tucatinib “game changing” against stage IV HER2+ breast cancer, especially with brain metastases

Phase III clinical trial results reported today in the New England Journal of Medicine and presented concurrently at the San Antonio Breast Cancer Symposium (SABCS) 2019 show the combination of the investigational drug tucatinib with standard of care treatment including the drugs trastuzumab and capecitabine nearly tripled one-year progression-free survival (33 percent vs. 12 percent), and nearly doubled the two-year overall survivor (45 percent vs. 27 percent) in women with HER2+ metastatic breast cancer. The international, multi-center trial, named HER2CLIMB (NCT02614794), builds on early development and clinical trials involving the  University of Colorado Cancer Center.

Author Cancer Center | Publish Date December 11, 2019
Full Story

Research    Breast Cancer

Three-drug cocktail of targeted therapies promising against hormone receptor and HER2 positive metastatic breast cancer

The growth of some breast cancers is driven by hormones like estrogen and progesterone. Other breast cancers are driven by changes in the gene HER2. Still some cancers are driven by both – and breast cancers whose growth can be controlled by hormonal receptors and HER2 can be especially tricky to treat. A University of Colorado Cancer Center phase 1b study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2019 offers an attractive alternative to the chemotherapy that is often used with these patients: the three-drug cocktail of targeted treatments – tucatinib, palbociclib and letrozole – was overall well-tolerated and showed preliminary evidence of promising anti-cancer activity. Results support the continued development of the combination in an ongoing phase 2 clinical trial.

“I see this as a promising chemotherapy-free combination for patients who have been without good options, especially for those whose disease has spread to the brain,” says Elena Shagisultanova, MD, PhD, investigator at CU Cancer Center and the trial’s principal investigator.

Tucatinib is a targeted HER2 inhibitor; palbociclib stops cancer cells from rushing through the cell cycle required for fast proliferation; and the anti-hormonal drug letrozole restricts the ability of cancers to drive growth using estrogens. Previous work has shown that palbociclib and letrozole combine to kill more cancer cells than letrozole alone. And lab work by Shagisultanova and her mentor Virginia Borges, MD, at CU Cancer Center led them to believe that tucatinib should be a potent addition to this combination.

Results of the current trial show that the theory holds up in humans: of 20 patients enrolled on the study since November 2018, 14 remained on study as of 1/4/2019, five of which had been on the study more than 6 months. The goal of the phase 1b study was to explore the safety of this combination, with no patients experiencing side effects that required study withdrawal.

“All these patients have metastatic breast cancer and up to five different treatments before trying this trial. Also, 45 percent have brain metastases. In this population, our results look promising,” Shagisultanova says.

A phase 2 trial further exploring the combination is offered at CU Cancer Center, University of Arizona, Northwestern University, New Mexico Cancer Care Alliance, Stony Brook University, and University of Texas Health Science Center San Antonio.

Author Cancer Center | Publish Date June 17, 2019
Full Story

CU Cancer Center In the News


Movie ‘distraction therapy’ improves children’s experience of radiation

news outletHealio
Publish DateJuly 15, 2021

In the 2016 animated film “Moana,” the title character bravely battled a volcanic demon and saved her people.

Full Story
La Voz

Skin Cancer Awareness

news outletLa Voz
Publish DateJuly 07, 2021

Now that summer has officially arrived, thoughts might be turning to a new seasonal look. But, before that, it might be wise to think about another look, one that results from spending too much time in the sun. Sunburn is not just an uncomfortable condition, it could be a precursor to skin cancer, the most common and potentially fatal cancer in the United States.

Full Story
MedPage Today

Hold Off on Approving Anal Cancer Drug, Advisors Tell FDA

news outletMedPage Today
Publish DateJune 24, 2021

FDA advisors told the agency to wait on more data before approving an investigational immunotherapy for squamous carcinoma of the anal canal (SCAC), largely due to questions over the drug's activity.

Full Story
The Denver Post

Radiation therapy as a pound of prevention? A ray of hope for pancreatic cancer patients, thanks to Wings of Hope

news outletThe Denver Post
Publish DateJune 20, 2021

Using radiation to kill malignant cells in the body is nothing new, but thanks in part to funding from Wings of Hope for Pancreatic Cancer Research, oncologists are continuing to explore newer applications for one of their more standard medical therapies.

Full Story